Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorinostat + melphalan + prednisone
- Development stage
- Phase 2
- Lead developer
- Tiziana Marangon
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Vorinostat + melphalan + prednisone (ZMP) is a combination regimen investigated for the treatment of relapsed or refractory multiple myeloma. Vorinostat (Zolinza) is a small molecule inhibitor of Class I and II histone deacetylases (HDAC), which induces cell cycle arrest and apoptosis in malignant cells. Melphalan is a nitrogen mustard alkylating agent that causes DNA cross-linking, and prednisone is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. This specific combination was evaluated in a Phase I/II clinical trial (NCT00857324) led by Tiziana Marangon at the University of Turin to determine if the synergistic effects of HDAC inhibition could enhance the efficacy of the standard melphalan-prednisone (MP) backbone in advanced myeloma patients.
- Other names
- vorinostat-melphalan-prednisoneSAHA + melphalan + prednisonesuberoylanilide hydroxamic acid + melphalan + prednisone
02
Targets
DNAGR (Glucocorticoid receptor)HDAC1 (Histone Deacetylase 1)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on vorinostat + melphalan + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorinostat + melphalan + prednisone.